Sanofi halts trial of Covid-19 drug Kevzara after tests prove inconclusive
Advertisement
PARIS: French pharma giant Sanofi said Tuesday that international Phase 3 clinical tests of its Kevzara drug for serious Covid-19 cases had proved inconclusive and it was halting the trial.
The Phase 3 test -- normally the last before official approval for use -- "did not meet the primary or secondary evaluation criteria compared with a placebo, and in both cases, compared with established hospital care," it said in a statement.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.